Anti-aging startup NewLimit hit a $3.1 billion valuation earlier this week, and Axios Pro spoke with CEO Jacob Kimmel on the fundraise and the company's strategy.
The FDA historically hasn't classified aging as a disease, making it difficult to get drugs in the space approved, but there are early signs that regulators may relent.
NewLimit plans to bring its first medicine, a liver drug, to human trial next year.
